Company Overview and News

6
Marcus Hiles - Texas in 2018 is Home to the Nation's Top Paying Companies

2018-09-14 accesswire - 1
DALLAS, TX / ACCESSWIRE / September 14, 2018 / The Business Journals publication network published their latest "In The Money" report last month where they analyzed more than 600 publicly traded companies to find the top paying organizations in the country. With many US cities historically falling second to the stronghold of tech companies dominating the west coast's Silicon Valley region, many were surprised that the new state leaders were named as Massachusetts and Texas.
INFI VLO

13
Infinity (INFI) Up 21.9% Since Last Earnings Report: Can It Continue?

2018-09-06 zacks - 1
A month has gone by since the last earnings report for Infinity Pharmaceuticals (INFI - Free Report) . Shares have added about 21.9% in that time frame, outperforming the S&P 500.
INFI RCUS CTLR KHC PE CLR

16
Constellation Pharmaceuticals Announces Appointments to Board of Directors

2018-09-04 globenewswire - 4
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Dr. Elizabeth G. Tréhu and Steven L. Hoerter have been appointed to its Board of Directors.
INFI JNCE AGIO CNST CLVS

11
Infinity Focuses on Developing IPI-549 for Solid Tumors

2018-08-22 zacks - 1
We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI - Free Report) on Aug 21.
INFI CELGZ RCUS GILD CELG

52
Verastem: An Undervalued Rare Oncology Gem With Big Upcoming Catalysts

2018-08-15 seekingalpha - 12
Duvelisib will be the only drug of its kind - a monotherapy PI3K dual inhibitor that can be taken orally at home without traveling to an infusion center.
INFI EXEL VSTM NVS YKLTF ABBV PFE ABBV

8
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2

2018-08-09 zacks
Infinity Pharmaceuticals, Inc. (INFI - Free Report) reported loss of 12 cents per share in second-quarter 2018, narrower than the Zacks Consensus Estimate of a loss of 20 cents. The company had reported a loss of 34 cents in the year-ago quarter.
INFI VRTX RCUS UCTI UCTT

5
INFI / Infinity Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-08-08 sec.gov
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INFI

5
INFI / Infinity Pharmaceuticals, Inc. 10-Q (Quarterly Report)

2018-08-07 sec.gov
Document Table of Contents
INFI

5
INFI / Infinity Pharmaceuticals, Inc. null

2018-07-20 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")-BG HE/^[email protected]&09&-&)_XR3_P $& #6NP?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
INFI

11
Rounds Report: Galmed Rallied Subsequent To The Overweight Rating Of Dr. Elemer Piros

2018-07-15 seekingalpha - 4
The overall bioscience market ended the second week of July with a mixed sentiment. Nevertheless, many equities under our coverage continued to rally and thereby procured more profits.
INFI MDGL GLMD IBB XBI

96
Infinity and Arcus Ink Deal for Two Triple Combo Studies

2018-06-27 zacks - 1
Infinity Pharmaceuticals, Inc. (INFI - Free Report) and Arcus Biosciences, Inc. (RCUS - Free Report) , entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types, which typically show minimal response to checkpoint inhibition monotherapy.
ANIP INFI RCUS AGLE ARW

72
INFI / Infinity Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-06-26 sec.gov - 3
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
INFI

71
Why Infinity Pharma Shares Are Booming

2018-06-26 247wallst - 2
Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares made a healthy gain early on Tuesday after the firm announced a collaboration with Arcus Biosciences Inc. (NYSE: RCUS). These two companies have entered into a clinical collaboration to evaluate two triple combination therapies in selected tumor types that typically show minimal response to checkpoint inhibition monotherapy.
INFI RCUS

69
Is the Options Market Predicting a Spike in Infinity (INFI) Stock?

2018-06-25 zacks
Investors in Infinity Pharmaceuticals, Inc. (INFI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jul 20, 2018 $2.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
INFI HFC

124
Infinity Pharmaceuticals: Cheap With A Key Data Readout Coming

2018-06-22 seekingalpha - 14
Strengthening of the leadership team, Board of Directors and establishment of Scientific Advisory Board is a green flag.
INFI VSTM

INFI : Infinity Pharmaceuticals Stock Analysis and Research Report

2017-11-07 - Asif

Infinity Pharmaceuticals is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity Pharmaceuticals is focusing its efforts on advancing IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma. Preclinical research has demonstrated that PI3K-gamma is highly expressed in tumor-associated macrophages and that blockade of PI3K-gamma signaling by treatment with IPI-549 results in a reprogramming of macrophages in the tumor microenvironment from the M2, or pro-tumor, phenotype to the M1, or anti-tumor, phenotype. This shift increased the number and activity of anti-tumor T cells that can attack the tumor and also increased the production of pro-inflammatory cytokines, which can further stimulate an anti-tumor immune response. Preclinical data from multiple solid tumor models demonstrated that IPI-549 was active as a monothe...

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to INFI / Infinity Pharmaceuticals, Inc. on message board site Silicon Investor.

Infinera Infinera Infinera Infineon Technologies Infineon Technologies Infineon Technologies
Infinity Pharmaceuticals Infinity Pharmaceuticals Infinity Pharmaceuticals Infinity Pharmaceuticals Inc (INFI) Infinity Pharmaceuticals Inc (INFI) Infinity Pharmaceuticals Inc (INFI)
From Here to InfiniBand From Here to InfiniBand From Here to InfiniBand Infinity Broadcasting(CBS) Infinity Broadcasting(CBS) Infinity Broadcasting(CBS)
Chemical biology Chemical biology Chemical biology IFLB - Infinium Labs, Inc. IFLB - Infinium Labs, Inc. IFLB - Infinium Labs, Inc.
Calian Technology a Company with infinite growth potential Calian Technology a Company with infinite growth potential Calian Technology a Company with infinite growth potential Infinite Group (IMCI) Infinite Group (IMCI) Infinite Group (IMCI)
CUSIP: 45665G303